Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pancreatic enzyme replacement flunked randomized trial

Publish date:: March 11, 2020

Key clinical point: Pancreatic enzyme replacement therapy after pancreatoduodenectomy did not significantly improve body weight.

Major finding: After 3 months of treatment, the PERT group lost an average of 0.68 kg and the placebo group lost an average of 1.19 kg (P = .302).

Study details: Randomized, multicenter, placebo-controlled trial of 304 patients who underwent pancreatoduodenectomy.

Disclosures: Korea Pharmbio and the Ministry of Science and ICT provided funding. The researchers reported having no conflicts of interest.

Citation:

Kim H et al. Clin Gastroenterol Hepatol. 2019 Sep 12. doi: 10.1016/j.cgh.2019.08.061.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

IBD patients prefer vedolizumab over anti-TNF drugs,

During pandemic, many gastroenterologists report low resilience, insomnia,